Physician profile
Amjad Bahnassi
NPI 1487754974
$352,092.72
in general payments reported to CMS, 2019-2025
35 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $21K · 2021: $40K · 2022: $56K · 2023: $70K · 2024: $51K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Food and Beverage: $20K · Consulting Fee: $20K · Travel and Lodging: $14K · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,191.65 |
| Food and Beverage | $20,350.44 |
| Consulting Fee | $19,915.00 |
| Travel and Lodging | $14,406.63 |
| Education | $212.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $79,994.14 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $71,331.97 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $60,981.00 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $43,045.03 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $22,010.22 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19,018.16 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $15,242.54 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $12,633.63 | 2021-2025 | Qelbree |
| Allergan, INC. | $8,866.77 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $6,479.71 | 2019-2025 | Ingrezza |
| Eisai INC. | $5,166.19 | 2020 | |
| Sunovion Pharmaceuticals INC. | $2,681.44 | 2019-2022 | |
| Lundbeck LLC | $874.95 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $750.41 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $676.02 | 2023-2025 | Sunosi, Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $611.21 | 2019-2024 | Trintellix |
| Corium, LLC | $412.66 | 2023-2025 | Azstarys, Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $296.69 | 2019-2020 | |
| Pfizer INC. | $146.02 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $132.49 | 2024 | Relexxii |
| Bausch Health US, LLC | $110.41 | 2023 | Aplenzin, Wellbutrin |
| Indivior INC. | $89.69 | 2022-2025 | Sublocade |
| Lilly USA, LLC | $82.92 | 2025 | Zepbound, Mounjaro |
| Shire North American Group INC | $74.52 | 2019 | |
| Neos Therapeutics, Lp | $69.20 | 2019-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $62.80 | 2020 | |
| Idorsia Pharmaceuticals US INC | $60.96 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $39.17 | 2019-2020 | |
| Tempus Ai, INC | $29.25 | 2024 | |
| Luye Pharma (USA) Ltd. | $28.69 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $24.84 | 2024 | |
| Braeburn INC. | $20.00 | 2024 | Brixadi |
| Avion Pharmaceuticals | $17.95 | 2023 | Methylphenidate Hydrochloride |
| Jazz Pharmaceuticals INC. | $17.31 | 2019 | |
| Merck Sharp & Dohme LLC | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Bahnassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.